The FDA has rejected Lykos Therapeutics’ New Drug Application for MDMA-assisted therapy for PTSD and requested an additional Phase 3 study.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
Lykos Therapeutics addresses concerns from FDA Advisors about MDMA-assisted therapy and presents a forward looking plan.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness